Therapeutic Options in Hepatorenal Syndrome with Acute Kidney Injury: Confirming the Value of Systemic Vasoconstriction

FACULTY

K. Rajender Reddy, MD
Director, Hepatology
Medical Director, Liver Transplantation
Penn Medicine
Philadelphia, PA

PROGRAM OVERVIEW

This enduring activity targets healthcare gaps related to the diagnosis, treatment, and individualized management of hepatorenal syndrome with acute kidney injury (HRS-AKI), impacting outcomes through diagnosis and differentiation from other forms of AKI as well as individualizing pharmacotherapeutic management.

• By addressing these gaps, you can assess whether your approach to HRS-AKI diagnosis and management through utilization of the latest clinical trial data on emerging pharmacotherapies – could be modified to help close these gaps.
• Expert discussion will guide you in analyzing and identifying challenges to HRS-AKI diagnosis and staging, the evolution of pharmacotherapies in HRS-AKI, and relevant clinical considerations to their application in case management.
• You will also be immersed in interactive, animated simulation case studies to memorably highlight key points related to assessment and treatment options in HRS-AKI.

TARGET AUDIENCE

This activity is designed to meet the educational needs of nephrologists, hepatologists, cardiorenal specialists, cardiologists, nurses, nurse practitioners, pharmacists, and other members of the multidisciplinary team to ensure an up-to-date understanding of the latest data in management of HRS-AKI.

LEARNING OBJECTIVES

• Formulate diagnostic and management strategies in HRS-AKI based on the current definitions and pathophysiologic findings
• Summarize therapeutic outcomes and the strength of evidence of clinical trials in HRS-AKI treatment
• Evaluate findings from clinical trials to assess the value of emerging pharmacotherapies for HRS-AKI

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses who want an up-to-date understanding of the latest data in the diagnosis and management of HRS-AKI.
CNE Credits: 1.0 ANCC Contact Hour

CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/Complete Conference Management is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.

Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturers of any commercial products and/or providers of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

K. Rajender Reddy, MD has consulted for Mallinckrodt Pharmaceuticals and Spark Therapeutics and has contracted research for BMS, Novartis, Exact Sciences, Grifols, and Sequana Medical.

CME Content Review

The content of this activity was independently peer-reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review

The content of this activity was peer reviewed by a nurse reviewer.

Douglas Cox, MSN, MHA, RN
Ultimate Medical Academy/CCM – Lead Nurse Planner

The reviewer of this activity has nothing to disclose.

Staff Planners and Managers

The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

• Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
• Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
• Douglas Cox, MSN, MHA, RN, UMA/CCM – LNP, has nothing to disclose.
• Nicole Longo, DO, FACOI, Director of Medical and Scientific Services for Med Learning Group, has nothing to disclose.
• Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
• Daniel Dasilva, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
• Ana Maria Albino, Senior Program Manager for Med Learning Group, has nothing to disclose.
• Natalie Smith, Program Coordinator for Med Learning Group, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this lecture, faculty may mention the use of medications for both FDA-approved and non-approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:

1. Read the CME/CNE information and faculty disclosures.
2. Participate in the enduring activity.
3. Complete pre-and-post surveys and evaluation.

You will receive your certificate as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science based.
This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at [email protected].

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]

 

Copyright © 2022 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.